Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. Director and COO of the Company, Dr. Gaurav Chandra, joined Stock Day host Everett Jolly.
"Could you tell us about IPF Immune™ and the success you're hoping it will bring to the Company?", asked Jolly to begin the interview. "IPF Immune™ is a science-backed immune modulator that helps strengthen the body's defenses against viruses or other pathogens," explained Dr. Chandra, adding that the product stimulates the body's natural immune system, without producing any side effects. "It works as an immune booster that increases the ability of the immune system to fight infections, and in addition it enhances recovery and reduces the recovery period after an illness."
"While we have already launched IPF Immune™ in the United States, we are also launching the product in Europe and Canada in the next three months," continued Dr. Chandra, noting the revenue potential of this product.
Dr. Chandra then elaborated on the significance of IPF Immune™, citing positive results during testing against the CoronaVirus (SARS-CoV-2) strain 229e. "It actually showed comparable efficacy, but with 24 times lower toxicity than the widely used antiviral, Tamiflu," said Dr. Chandra, noting the product's additional applications. Additionally, he said that our preliminary studies with IPF-Immune have demonstrated significant in-vitro neutralization activity against Adenovirus. "In the next couple of weeks, we will be sharing efficacy data with our shareholders."
"Do you have any revenue projections for IPF Immune™ going forward?", asked Jolly. "We do have revenue projections, and they are extremely healthy projections," shared Dr. Chandra. "The immune modulator market is large and growing," he added. "It's a $50 billion nutritional supplement market, so we expect significant revenues in the upcoming year."
Jolly commented on the Company's numerous product platforms, including their patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), as well as their monoclonal antibody program, and asked what makes the Company so special. "We have identified the conserved immutable targets in about 20 viruses, and then we went a bit further," said Dr. Chandra. "We built AI-based three-dimensional models of these immutable targets and established linearity, neutralization by antibodies or accessibility by antibodies, before moving forward to develop monoclonal antibodies that target these specific sequences."
"We actually did the same thing for HIV viruses," he continued. "We identified 8 conserved immutable targets," said Dr. Chandra. "The virus can mutate many times, but since these are conserved it will remain unchanged," he explained. "The resulting monoclonal antibodies that we have created are universal, durable, broadly utilizing, and will remain unaffected by mutations or viruse escape."
Dr. Chandra then discussed the importance of AI-driven diagnostics. "We are discussing partnerships with diagnostic companies that have a track record of getting diagnostics tests through Regulatory approval and distributing these diagnostic tests for clinical use.," said Dr. Chandra. "As viruses mutate, the diagnostic test for them have to be modified to identify each mutant of the virus," he said. "But since the targets we have identified remain unchanged, if those target sites are used to diagnose the virus, then you have a test that is universally applicable even for mutants of the viruses."
Talking about AI-driven prognostics he said that there are documented studies showing better prognosis and clinical outcomes in patients with antibodies to the AI-identified conserved targets. Enzolytics is also discussing a potential partnership to develop a prognostic test that predicts immune response before receiving a vaccine or antiviral therapy.
"Since we have the capability of identifying conserved targets, we are actually working to be a part of consortiums that are looking to prevent the next global pandemic, and that is very exciting for us," shared Dr. Chandra. "The AI platform significantly cuts down the time for our drug discovery and development."
"Where is Enzolytics at with collaborations moving forward?", asked Jolly. "At Enzolytics, we build a product and put effort into R&D, and then we intend to partner with a larger entity, a large pharmaceutical company, that can take it through the clinical stages quickly," said Dr. Chandra. "We need to make sure our products reach patients as soon as possible."
"Have you considered where your valuation may end up six months to two years from now?", asked Jolly. "The market cap is not reflecting the full potential of Enzolytics," said Dr. Chandra, noting the significant market for each of the Company's products. "The next product that we have is ITV-1, which is an HIV therapeutic and has actually cleared Phase III clinical trials and is preparing for introduction into two markets," he explained. "The African market is a significant market because 65% of about 34 to 37 million HIV infected individuals live in Africa."
"We will also be introducing this product into Europe, and are currently awaiting certification under the European Medical Agency," shared Dr. Chandra.
"The global monoclonal antibody market is significant; we are looking at a $144 billion market," continued Dr. Chandra. "We have four monoclonal antibodies for infectious diseases that are in clinical development as we speak."
"As you can imagine, although the market is not reflecting the actual market cap of the company, in the next six months to one year we anticipate a monumental shift in the position of the company as our clinical products start coming to the market ," said Dr. Chandra.
To close the interview, Dr. Chandra encouraged listeners and shareholders to keep up to date with the Company's updates and current projects as they continue to make significant progress across its multiple therapeutic platforms.
To hear Dr. Chandra's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8084060-enzolytics-inc-discusses-the-significance-and-revenue-potential-of-its-therapeutic-platforms-wi
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
The Company is also implementing its proprietary technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. In addition, its proprietary methodology, covered in its pending U.S./PCT Patent Application for producing fully human monoclonal antibodies, is currently employed to produce monoclonal antibody therapeutics for numerous infectious diseases, including the CoronaVirus (SARS-CoV-2) and HTLV-1.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
I.R. contact:
Enzolytics Inc.
Company Contact:
Enzolytics, Inc.
Texas A&M Institute for Preclinical Studies
Enzolytics, Inc.
800 Raymond Stotzer Parkway
College Station, Texas 77843-4478
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
SOURCE:
Stock Day Media
(602) 821-1102
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/124101
